Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:04 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Vitamin K Supplementation on Circulating Levels of Osteocalcin on the Bone Metabolism and Aging
NCT04669782 · University of Milano Bicocca · NA · terminated · last registry update 2025-07-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Logistics/management problems at the recruiting center” | – | Registry record, University of Milano Bicocca |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PTH1R within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-07-16Phase 3 first posted: Ascendis Pharma A/S, Palopegteriparatide (NCT07706764)
- 2026-06-05Results posted on the registry: University of Wisconsin, Madison, Abaloparatide (NCT04167163)
- 2025-11-25Also stopped (withdrawn): Massachusetts General Hospital, a drug against PTH1R (NCT03232476)
- 2025-07-24Phase 3 first posted: Ascendis Pharma Bone Diseases A/S, Palopegteriparatide Experimental Arm + Palopegteriparatide Control Arm (NCT07081997)
- 2025-06-19Phase 3 first posted: Shenzhen Salubris Pharmaceuticals Co., Ltd., SAL056 (56.5μg) + Alendronate (NCT07028320)
- 2025-03-27Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., QLG2128 + Teriparatide Injection (NCT06898060)
- 2025-02-28Results posted on the registry: Ascendis Pharma Bone Diseases A/S, TransCon PTH + Placebo (NCT04701203)
- 2024-09-19Results posted on the registry: David Lunardini, Abaloparatide (NCT04760782)
- 2024-09-19Also stopped (terminated): David Lunardini, Abaloparatide (NCT04760782)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision